Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells

Epratuzumab has demonstrated therapeutic activity in patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia, systemic lupus erythematosus, and Sjögren's syndrome, but its mechanism of affecting normal and malignant B cells remains incompletely understood. We reported previously that e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:MAbs
Egile Nagusiak: Chang, Chien-Hsing, Wang, Yang, Gupta, Pankaj, Goldenberg, David M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2014
Gaiak:
Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622945/
https://ncbi.nlm.nih.gov/pubmed/25484043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/19420862.2014.979081
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak